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GENOMICS OF ASTHMA 
Abstract 
 
Asthma is one of the most common heritable diseases globally, with highly variable clinical 
expression and response to treatment that is attributed to underlying genetic differences.  
Hundreds of loci on multiple chromosomes are associated with asthma.  Genetic testing is not 
currently recommended for management, however, recognition of common asthma phenotypes, 
which are the result of genetic and environmental interactions, can help to guide treatment 
decisions.  Asthma phenotypes are divided into two major categories of atopic and non-atopic 
disease, with further subdivisions within in each category that are associated with patterns in 
clinical presentation and responsiveness to treatment.  In general, earlier onset, and allergic 
disease will respond well to traditional therapy with inhaled corticosteroids and leukotrienes, as 
these medications target corresponding inflammatory pathways for allergic disease.  However, 
patients with late onset, symptom predominant (lacking inflammation) and obese asthma may be 
resistant to standard therapy and may require treatment modification.  These patients are at risk 
for overuse of inhaled corticosteroids with poor response, and may benefit more by use of long 
acting beta agonists, long acting muscarinic agonists, weight reduction, and exercise.  Research 
into genetic testing for responsiveness to common asthma medications is early stage, but shows 
evidence of clinically utility and cost effectiveness. 
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Asthma is one of the most common chronic health conditions world-wide, affecting 
approximately 8.3% of U.S adults and children 1.  Like many common conditions, it tends to run 
in families, and individuals with a family history of asthma are four to six-times more likely to 
develop disease, with estimates of heritability ranging from 25 to 95% 2.  Albeit a common 
diagnosis, asthma is now recognized as a highly heterogenous syndrome that can present 
differently from person to person.  This variation in individual expression is attributed to a 
complex interplay of genetic and environmental factors, which are currently only partially 
understood 2.   Socioeconomic and environmental influences have been long recognized as 
significant factors and targeted for intervention.  However emerging evidence suggests that 
genetic determinants are equally important in the expression and progression of disease, and 
research in this area is rapidly gaining focus.   
Two primary approaches have been used to identify genes related to development of 
asthma: linkage studies and genome wide association studies (GWAS).  Linkage studies examine 
family members with and without asthma and look for significant patterns in their DNA that 
correspond to clinical expression of disease. GWAS, on the other hand, are large-scale 
population studies that do not rely on families, in which researchers sequence the entire DNA of 
individuals with disease and compare to ethnically-matched individuals without disease to 
determine if specific genetic patterns or variants are associated with phenotypes or traits.  
Evidence from these studies suggests that asthma has a multifocal, mixed dominance inheritance 
pattern (both recessive and autosomal dominant), involving over 100 individual loci on each 
chromosome and more than 20 independent chromosomal regions (consisting of millions of 
bases) 2,3.  However, research is early stage in these areas, and the precise role of individual 
genes in expression of asthma remains ambiguous.   
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The broad scope for genetic variability helps to explain the marked diversity seen in 
clinical practice.  When a disease is caused by a consistent or small group of genes (genetic 
homogeneity) there is generally greater uniformity in disease expression and therapeutic 
response.  Because asthma is caused by hundreds of susceptibility genes interacting differently 
with each other and the environment, there is potential for substantial heterogeneity in 
expression of disease and response to treatment. In fact, it is estimated that genetic factors may 
not only account for differences in disease severity, but also for up to 70% of variability in 
response to inhaled corticosteroids and 92% of variability in response to short acting beta 
agonists 4,5.   One such example is Indacaterol, a newer long acting beta agonist currently 
approved for treatment of COPD/chronic bronchitis, which is occasionally used in the treatment 
of severe asthma.  Indacaterol is metabolized by through the UGT1A1 pathway, which is 
encoded by a gene complex located on chromosome two 6.  Genetic variation at this loci has 
been found to result in reduced or absent UGT1A1 activity, with subsequently altered medication 
metabolism and marginally higher serum levels at steady state, which may be related to variable 
response to this medication 7.  Similarly, multiple gene segments have been identified in 
relationship to inhaled corticosteroid (ICS) metabolism, and preliminary evidence suggests that 
genetic testing for steroid responsiveness may ultimately prove to be both cost and clinically 
effective 8.  Presently, these tests are not available for mainstream use.  However, as the field of 
pharmacogenetics continues to develop, it is likely that genetic testing will play a greater role in 
clinical management, as it might be used to predict how patients will respond to treatment and 
guide future treatment approaches.  A list of known medication-genetic interactions with 
potential biomarkers is available at the Food and Drug Administration website, and includes long 
acting beta agonists (LABA) such as Aformoterol and Formoterol 9. 
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At present, genetic testing is not routinely indicated, and treatment is more usefully 
guided by asthma phenotype. Phenotypes are the observable characteristics of disease that result 
from interactions of genes and environment—i.e. how the patient presents clinically and 
responds to therapy.  There are some exceptions to this rule, and patients with poor response to 
treatment or suspicion of other asthma look-alikes, such as bronchiectasis, ciliary dyskinesia, or 
alpha I anti-tripsin disorder, warrant specialty referral and may require further testing 10.   In 
most circumstances, however, asthma phenotypes can be recognized based on observable 
characteristics, such as allergic versus non-allergic disease, responsiveness to inhaled steroids, 
age of onset (pediatric versus adult onset), and comorbid obesity 11. 
Albeit having similar symptoms (e.g. chest tightness, wheeze, cough), the precipitating 
pathology and corresponding approaches to treatment differ by phenotype.  While there is no 
universal consensus, there appear to be approximately five to seven distinct groups, depending 
on source 11.  These have been broadly classified into two primary groups: atopic (eosinophilic) 
and non-atopic (non-eosinophilic) asthma, also commonly referred to as allergic/non-allergic or 
intrinsic/extrinsic asthma 5. In this paper we adhere to "atopic" which infers that the host has a 
genetic tendency to produce eosinophils and IgE antibiodies in response to antigens which are 
surface markers found on the surface of allergens.   
Atopic asthma phenotypes are now recognized to be further subdivided into early onset 
(mild, moderate, and severe), late onset (usually severe), and inflammation predominant, the 
latter of which presents with fewer symptoms but is associated with mixed eosinophilic and 
neutrophilic inflammation and heightened pulmonary remodeling 11.  Details on similarities and 
differences between phenotypes are presented in Table 1. Non-atopic asthma phenotypes include 
late onset obese and symptom predominant asthma, which notable for high levels of symptoms 
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but without eosinophilic inflammation.  Atopic obese asthma is also clinically distinct from non-
atopic obese asthma and can be distinguished by early age of symptom onset with evidence of 
allergic inflammation 12.  Other sources further categorize phenotypic variations based on 
precipitating factors, such as trigger-induced, infection-related, and Asprin-induced respiratory 
disease, however these have not been tied to variable treatment responses and may be less 
relevant clinically 13.   
While knowing specifically which genotype precede each phenotype is not necessary, 
ability to identify phenotypes is useful, as responsiveness to treatment does varies between the 
phenotypes listed in Table 1 13.  Specifically, the majority of control medications used to treat 
asthma, such as inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA), and 
more recently anti-IgE monoclonal antibody therapy, work by inhibiting allergic inflammatory 
pathways, and are thus not as effective for non-atopic asthma.   
Allergic inflammation is mediated by the adaptive immune system via IgE antibodies, T 
helper cells, and eosinophils.  IgE-mediated inflammation has rapid onset following allergen 
exposure and may be associated with severe or anaphylactic reactions.  In this situation, IgE 
antibiodies recognize antigens (markers) on the surface of an allergen, such as pet dander.  This 
triggers IgE to bind to pro-inflammatory immune cells (mast cells) which trigger release of T 
helper type 2 cells (Th2) and histamine, the latter of which is cytotoxic and causes immediate 
inflammation.   Eosinophils, the other hallmark of allergic asthma, are triggered by the release 
interluekins from the Th2 cells 10.  This causes further inflammation and increased bronchial 
hyperresponsiveness.  Thus, atopic asthma is commonly referred to as eosinophilic asthma, and 
when severe, Th2 type asthma.  Mainstay asthma medications such as ICS and LTRA 
specifically target Th2 mediated cytokines, and block the allergic pathways at multiple levels, 
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thereby preventing inflammation and symptoms of asthma.  Similarly, anti-IgE biotherapy 
blocks free serum IgE and prevents initiation of mast cells, histamine and Th2 cells, again 
inhibiting the allergic inflammatory pathway. 
In contrast to atopic asthma, late onset obese asthma and symptom predominant asthma 
phenotypes lack inflammatory pathology via the adaptive immune system and instead trigger 
symptoms via T helper type 17 (Th17) pathways, which release an entirely different group of 
pro-inflammatory mediators (including neutrophils) that can directly cause bronchial 
hyperreactivity with or without inflammation 10.  It is critical to note that cytokines produced by 
Th17 are not responsive to steroids.  Patients with obese and symptom predominant asthma 
phenotypes will therefore respond poorly to traditional treatment with ICS and LTRA, and are at 
risk for overuse of ICS with minimal benefit 11.  Furthermore, in individuals with obese asthma, 
mechanical limitations on respiration (i.e. chest wall adipose tissue) can induce further bronchial 
hyperresponsiveness and trigger symptoms without underlying inflammation 12.  Thus, 
individuals with non-allergic asthma may require a different approach to treatment, and may 
derived greater benefit from use of long-acting muscarinic agonists (LAMA) or long acting beta-
agonists (LABA), both of which induce smooth muscle relaxation and alleviate symptoms by 
targeting bronchospasm rather than inflammation 12. It is also important to recognize that there 
may be overlap between phenotypes, with varying degrees of expression of Th2 and Th17 
pathways, which further contributes to heterogeneity of response to treatment and the complexity 
of clinical management. 
In conclusion, asthma is no longer considered a single disease entity, but is now viewed 
as a syndrome comprising multiple phenotypic variations.  While genetic testing is not currently 
indicated, these variants present clinically with different observable characteristics and responses 
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to treatment that are based upon underlying genetic differences and interactions of genes with 
environmental factors.  Future clinical management of asthma is likely to be increasingly guided 
by pharmacogenetics and tailored treatments that target phenotypes specifically.  Clinicians 
should be aware of current phenotype classifications, monitor for expected responses to 
treatment, adjust medication therapy accordingly, and refer to specialist care when expected 
outcomes are not achieved. 
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Table 1. Asthma phenotypes and clinical features 
Phenotype Symptoms Pathology Clinical features 








Low symptom levels  
High sputum eosinophilia,  
Elevated FeNO  
Higher dose ICS + LTRA 
+/- LABA 
+/- Anti-IgE 
Early Onset  
Atopic (mild) 
Low Th2: Eosinophilic  Atopic 
High symptom levels  
High sputum eosinophilia  
Elevated FeNO 
Low to medium dose ICS  
or LTRA 
+/- LABA 





Th2: Eosinophilic Atopic 
High symptom levels  
High sputum eosinophilia  
Elevated FeNO 
Higher dose ICS 
+/- LABA 
Consider adding LTRA 
Anti-IgE if not controlled 
Late Onset  
Atopic 
(Severe) 
Very high Th2: Eosinophilic Atopic 
High symptom levels  
High sputum eosinophilia  
Elevated FeNO 
Not fully reversible with SABA 
Higher dose ICS 
+/- LABA 
Consider adding LTRA 




Very high Non-eosinophilic Normal eosinophils counts  
Normal FeNO,  
May have COPD overlap 
Poor response to ICS 
Consider:  LABA/LAMA 
Late Onset  
Obese 
High Non-eosinophilic Normal eosinophils counts  
Normal FeNO  
Decreased pulmonary function 
due to weight 
Average BMI = 33 
Poor response to ICS 
Weight loss 
Consider:  LABA/LAMA 
Notes:  BMI=Body mass index; FeNO=Nitric oxide; ICS=Inhaled corticosteroid; LABA= Long acting beta agonist; LAMA=Long acting muscarinic agonist; LTRA=Leukotriene receptor 
antagonist; SABA=Short acting beta agonist; Th2=T helper type 2 cell; Th17=T helper type 17 cell 
